Coya Therapeutics, Inc. Stock-Based Compensation
Coya Therapeutics, Inc. (COYA) reported Stock-Based Compensation of $3.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- Coya Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $943.91K, a 8.86% decline year-over-year.
- Coya Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.20M, a 103.27% increase year-over-year.
- Coya Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.10M, a 39.60% increase year-over-year.
- Coya Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.07M, a 38.18% increase year-over-year.
- Coya Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $4.29M, a 61.08% increase from fiscal 2024.
- Coya Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $2.66M, a 205.36% increase from fiscal 2023.
- Coya Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $872.25K, a 320.67% increase from fiscal 2022.
- Coya Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $207.35K, a 11.10% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $943.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.14M 10-Q · filed 2026-08-11 | $4.24M derived: sum of 3 quarters · filed 2026-08-11 | $5.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.20M 10-Q · filed 2026-05-12 | $3.30M derived: sum of 2 quarters · filed 2026-05-12 | $4.37M derived: sum of 3 quarters · filed 2026-05-12 | $5.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.17M derived: sum of 2 quarters · filed 2026-03-16 | $3.21M derived: sum of 3 quarters · filed 2026-08-11 | $4.29M 10-K · filed 2026-03-16 |
| 2025-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.11M derived: sum of 2 quarters · filed 2026-08-11 | $3.19M 10-Q · filed 2025-11-12 | $3.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $2.12M 10-Q · filed 2026-08-11 | $2.91M derived: sum of 3 quarters · filed 2026-08-11 | $3.68M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.08M 10-Q · filed 2026-05-12 | $1.87M derived: sum of 2 quarters · filed 2026-05-12 | $2.65M derived: sum of 3 quarters · filed 2026-05-12 | $3.31M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $790.55K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.57M derived: sum of 2 quarters · filed 2026-03-16 | $2.23M derived: sum of 3 quarters · filed 2026-03-16 | $2.66M 10-K · filed 2026-03-16 |
| 2024-09-30 | $775.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.44M derived: sum of 2 quarters · filed 2025-11-12 | $1.87M 10-Q · filed 2025-11-12 | $2.11M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $662.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.10M 10-Q · filed 2025-08-12 | $1.34M derived: sum of 3 quarters · filed 2025-08-12 | $1.60M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $435.66K 10-Q · filed 2025-05-13 | $673.66K derived: sum of 2 quarters · filed 2025-05-13 | $936.41K derived: sum of 3 quarters · filed 2025-05-13 | $1.13M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $238.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $500.75K derived: sum of 2 quarters · filed 2025-03-18 | $691.86K derived: sum of 3 quarters · filed 2025-03-18 | $872.25K 10-K · filed 2025-03-18 |
| 2023-09-30 | $262.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $453.86K derived: sum of 2 quarters · filed 2024-11-06 | $634.25K 10-Q · filed 2024-11-06 | $705.68K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $191.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $371.50K 10-Q · filed 2024-08-12 | $442.93K derived: sum of 3 quarters · filed 2024-08-12 | $512.76K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $180.39K 10-Q · filed 2024-05-09 | $251.82K derived: sum of 2 quarters · filed 2024-05-09 | $321.65K derived: sum of 3 quarters · filed 2024-05-09 | $366.31K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $71.43K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $141.26K derived: sum of 2 quarters · filed 2024-03-19 | $185.92K derived: sum of 3 quarters · filed 2024-03-19 | $207.35K 10-K · filed 2024-03-19 |
| 2022-09-30 | $69.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $114.49K derived: sum of 2 quarters · filed 2023-11-08 | $135.92K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $44.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $66.08K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $21.43K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $233.22K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |